Scholars Central

Conference abstractPublished 5 Aug 2013

Phase II clinical trial on synchronous Livin peptide-loaded dendritic cell vaccine and radiotherapy in advanced NSCLC patients

Authors: Jian-Guo Sun, Lu-Ping Zhang, Zheng-Tang Chen, Bin Lu

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: Our previous study demonstrated that Livin, an inhibitor of apoptosis proteins (IAP), could be a radio sensitizer in non-small cell lung cancer (NSCLC) and a good molecular target for autologous dendritic cell (DC) immunotherapy which was approved as Class III medical technology by General Logistics Department of PLA. Thus we carried out a phase II clinical trial on synchronous Livin peptide-loaded DC vaccine and radiotherapy in advanced NSCLC patients, which was registered at Chinese Clinical Trial Registry Objective: To explore the efficacy, safety, and immunologic effect of synchronous Livin peptide-loaded DC vaccine and radiotherapy in NSCLC patients. Methods: By Dec 2014, 118 advanced NSCLC patients who received 3-4 cycles of chemotherapy will be enrolled, of which 78 cases given radiotherapy alone (control group) and 40 cases given extra Livin peptide-loaded DC therapy synchronously (test group). Three HLA restricted epitope peptides of Livin, KWFPSCQFLL (HLA-A24), RLQEERTCKV (HLA-A2) and RLWEERTCK (HLA-A3), were synthesized. Radiotherapy in the control group was executed 2 Gy per fraction, 5 fraction per week to a total dose of 60-66 Gy. In addition to undergoing the same dose of radiotherapy, DC loaded with Livin peptides was subcutaneously injected in the test group every week for 4-5 weeks starting from the 6 th irradiation. The primary endpoint was progression-free survival (PFS), and secondary endpoints were response rate (RR), side effects, immunologic effect and performance status (PS). Results: By May 2013, 98 cases have been enrolled consisting of 68 cases in the control group and 30 cases in the test group. 85 cases have finished the treatment with 65 cases in the control group and 20 cases in the test group. The analysis of raw data showed that the objective response rate (ORR) in the test and control groups was 80% and 55%, respectively; the grade 2 and above radiation pneumonitis (RP) in the test and control groups was 13.5% and 21%, respectively, and the immunologic effect (IL-2, IFN, CD4/CD8, etc) was stronger in the test group than in the control group. No unaccepted side effects were observed in the test group. Conclusions: Preliminary results indicate certain advantage of Livin peptide-loaded DC plus radiotherapy over radiotherapy alone in advanced NSCLC patients. The conclusions will be made after the completion of enrollment and follow-up.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Translational Medicine.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalTranslational Medicine
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Jian-Guo Sun”
  • BylineArticles whose byline prints “Lu-Ping Zhang”
  • BylineArticles whose byline prints “Zheng-Tang Chen”
  • BylineArticles whose byline prints “Bin Lu”